Spending on glucagonlike peptide1 receptor agonists, or GLP1s, in the United States increased over 500% from $13.7 billion in 2018 to $71.7 billion in 2023, according to the Journal of the American Heart Association, Although these medications were initially developed to treat Type 2 diabetes, newer indications now include weight management
It provides a safe and effective way for people who find it hard to lose weight using traditional methods
Following her candid 2026 confession that these medications are a tool rather than a cheat the global conversation regarding weight shame has officially entered the Enough era
JorsalAKistorpCHolmagerPTougaardRSNielsenRHnselmannAet alEffect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial
The mechanism works through appetite suppression, delayed gastric emptying, and improved insulin sensitivity
Think of a peptide as a stimulant or super-vitamin for your pituitary to work more effectively